Articles tagged "Safety"

2019 American Transplant Congress
Effect of Induction Therapy on Outcomes of De Novo Renal Transplant Recipients Receiving Everolimus with Reduced-Dose Calcineurin Inhibitor: 24-Month Results from the TRANSFORM Study
R. Oberbauer¹, F. Vincenti¹, O. Viklicky¹, U. Huynh-Do¹, D. Kim¹, J. M. Cruzado¹, Y. Qazi¹, M. S. Kim¹, P. Narvekar², M. P. Hernandez Gutierrez², P. Bernhardt², D. Kuypers¹
¹TRANSFORM Study Group, Basel, Switzerland, ²Novartis Pharma AG, Basel, Switzerland
*Purpose: To assess the effect of induction therapy on efficacy and safety outcomes of de novo renal transplant recipients (RTxR) receiving everolimus with reduced calcineurin…
2019 American Transplant Congress
The Response to Human Papillomavirus Vaccination in Pediatric Patients before and after Kidney Transplantation
C. Nailescu¹, R. D. Nelson², K. Twombley³, P. S. Verghese⁴, A. S. Chishti⁵, M. Mills⁶, J. E. Slaven⁷, J. D. Mahan⁸, M. L. Shew¹
¹Riley Hospital for Children, Indianapolis, IN, ²Primary Children’s Hospital, Salt Lake City, UT, ³MUSC Children’s Hospital, Charleston, SC, ⁴Children’s Hospitals and Clinics of Minnesota, Minneapolis, MN, ⁵Kentucky Children’s Hospital, Lexington, KY, ⁶C.S. Mott Children’s Hospital, Ann Arbor, MI, ⁷Indiana University, Indianapolis, IN, ⁸Nationwide Children’s Hospital, Columbus, OH
*Purpose: Kidney transplant (KT) recipients have an increased incidence of malignancies, including Human Papillomavirus (HPV)-associated cancers. Thus, HPV vaccines may have an important role in…
2019 American Transplant Congress
Opioid Minimization in Kidney Transplant: Achievable Quicker Than You Think
J. N. Fleming, N. Patel, H. Gonzales, N. A. Pilch, S. Parks, C. Perez, P. K. Baliga, S. N. Nadig, D. J. Taber, V. Rohan
Medical University of South Carolina, Charleston, SC
*Purpose: Opioid use after kidney transplant has been shown to be a risk factor for chronic opioid use, which leads to an increased risk of…
2019 American Transplant Congress
Timeline for Resuming Physical Activities after Renal Transplantation: A Mid West Pediatric Nephrology Consortium Study
P. Baddi¹, H. Patel², H. Janjua³, D. Y. Kim⁴, A. Jain⁵
¹Beaumont Children's Hospital, Royal Oak, MI, ²Nationwide Children's Hospital, Columbus, OH, ³Cleveland Clinic Children's Hospital, Cleveland, OH, ⁴Children's Hospital of Michigan and Henry Ford Hospital, Detroit, MI, ⁵Children's Hospital of Michigan, Detroit, MI
*Purpose: To assess the practice patterns of the timeline for safely resuming various physical activities after pediatric kidney transplant.*Methods: An anonymous web-based survey was distributed…
2019 American Transplant Congress
Combination of Extended-Release Tacrolimus Plus Everolimus Once Daily in De Novo Kidney Transplant Recipients: ER-Tac vs LCPT
G. Spagnoletti, M. P. Salerno, F. De Gennaro, J. Romagnoli, F. Citterio
Surgery, Renal Transplant Unit, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy
*Purpose: Combination of Everolimus (EVR) with Tacrolimus (Tac) permits reduced calcineurin inhibitors exposure and, recently, has been demonstrated safe and effective. Two different once-daily Tacrolimus…
2019 American Transplant Congress
Impact of Revised Policy for Hepatocellular Carcinoma MELD Exception Points on Recurrence after Liver Transplantation
P. Le¹, L. McClelland¹, K. Knapp¹, T. Xu¹, S. Pelletier²
¹University of Virginia, Charlottesville, VA, ²Surgery, University of Virginia, Charlottesville, VA
*Purpose: On October 8, 2015, a revised liver policy regarding HCC exception scores was implemented with the intention to create a better balance in transplant…
2019 American Transplant Congress
Assessment of Proteinuria Reported as Adverse Events in De Novo Renal Transplant Recipients Receiving an Everolimus-Based Regimen: 24-Month Results from TRANSFORM
C. Legendre¹, S. Berger¹, F. Oppenheimer¹, A. Wiseman¹, S. Steinberg¹, O. Viklicky¹, G. Russ¹, R. Danguilan¹, N. Basic-Jukic¹, E. Mor¹, P. Narvekar², M. P. Hernandez Gutierrez², P. Bernhardt², C. Sommerer¹
¹TRANSFORM Study Group, Basel, Switzerland, ²Novartis Pharma AG, Basel, Switzerland
*Purpose: mTOR inhibitors (eg, everolimus [EVR]), are thought to increase the risk of post-transplant (Tx) proteinuria (PU). Here, we assess PU onset and outcomes in…
2019 American Transplant Congress
Endovascular Repair Of Abdominal Aortic Aneurysms In Kidney Transplant Recipients
S. Kwon¹, D. Jung¹, Y. Kim¹, S. Park², S. Yoon²
¹Department of Vascular and Transplant Surgery, The Catholic University of Korea, Seoul St. Mary's Hospital, Seoul, Korea, Republic of, ²Department of Vascular and Transplant Surgery, The Catholic Universtiy of Korea, Seoul St. Mary's Hospital, Seoul, Korea, Republic of
*Purpose: The possibility to diagnosis abdominal aortic aneurysm (AAA) in patients who underwent kidney transplantation (KT) is increasing. Immunosuppressive agents may effect on AAA progression.…
2019 American Transplant Congress
Outcomes for Liver Transplant Recipients on Renal Replacement Therapy: Who Cannot Wait for Safety Net
A. Pita¹, N. Kaur¹, M. Lo², A. F. Sabour¹, V. Tristan¹, Y. Genyk¹, M. K. Nadim³, L. Sher¹
¹Department of Surgery, Keck Medical Center of USC, Los Angeles, CA, ²Department of Preventive Medicine, Keck Medical Center of USC, Los Angeles, CA, ³Department of Medicine, Keck Medical Center of USC, Los Angeles, CA
*Purpose: The purpose of this study is to identify risk factors for poor outcomes for liver transplant (LT) recipients on renal replacement therapy (RRT) in…
2019 American Transplant Congress
Page Kidney Phenomenon in a Trauma Patient: A Case Report and Recommendations for Management
M. M. Estrada, D. R. Hall, W. Dar, J. S. Bynon
University of Texas Health Science Center at Houston, Houston, TX
*Purpose: Unintentional injuries result in over 30 million emergency room visits annually in the United States. With almost 20 thousand renal transplants performed in 2017,…